A revolutionizing way to combat type 2 diabetes, independent of the insulin pathway

Purpose and goal

The aim with the project is to develop unique and patentable compounds that will become drugs for the treatment of type 2 diabetes (T2D). We have according to plan shown that our model compounds work well in in vitro and in vivo in models regarded as being predictable for humans. In addition, we have developed new unique compounds from a lead and a back-up series. Several of these work well in cell based assays and some also in vivo. A number of new patent applications have been submitted.

Expected results and effects

Proprietary compounds showing good effect in vitro have been developed and some of these also work well in vivo. No side-effects have been observed. We have in in vivo systems considered to be predictive for the treatment of T2D in humans obtained good results. We have also been able to draw conclusions about how our compounds interacts with its target. Several new patent applications have been submitted.

Planned approach and implementation

By testing model compounds in in vivo models we have shown that our concept to treat T2D is valid. Based on the results we have managed to develop several unique and patentable compounds that work very well in vitro. The most promising compounds have also been tested in vivo, and work well there too. The next step is to further profile the most promising compounds to be able to select a candidate drug.